A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,330actual
Sites
5
Countries
Canada, France, Germany +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-02 | actual | When the study began enrolling |
| Primary completion | 2026-01-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
Intervention
- Other: No treatment given
Primary outcomes
what the primary-completion date above is the date OFDescription of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors
measured At the time of survey (Day 1)
Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors
measured At the time of survey (Day 1)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed